THE IMPACT OF TRANSCATHETER AORTIC VALVE IMPLANTATION IN PATIENTS WITH AORTIC STENOSIS

  • Andra OANCEA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Maria-Luiza COBZEANU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Cristina FURNICA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Raluca Ozana CHISTOL “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • M. ENACHE “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • A. TARUS “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Flavia CORCIOVA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Alina-Cristina ILIESCU Cardiovascular Disease Institute, Iasi, Romania
  • Elena DEJU Cardiovascular Disease Institute, Iasi, Romania
  • Gr. TINICA “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

Aortic stenosis (AS) is the most common valvopathy in elderly patients, with an increasing prevalence due to aging process of population, current guidelines recommending transcatheter aortic valve implantation (TAVI) as a choice of intervention. Frailty is an important predictor of outcomes in AS patients who undergo TAVI, but there is no consensus in its preoperative evaluation. Aim: to compare the clinical outcomes of TAVI with conventionally surgically treated patients. Material and methods: The data of all aortic valve procedures performed in over 65 years patients, treated at Cardiovascular Institute from Iasi (January 2015-September 2019) were analyzed. The propensity score was used to compare the prognostic of patients. Results: The target group included 70 patients referred to TAVI compared to a second group of 98 patients who undergone surgical aortic valve replacement (SAVR). The mean age of TAVI patients was higher than SAVR group (76.47 vs. 64.37). The heart failure associated with the valvular pathology was more severe in the TAVI group (61.43% patients included NYHA class III and 35.71% patients NYHA class IV) compared to the SAVR group (58.16% patients were NYHA class III and 7.14% patients were NYHA class IV). Atrial fibrillation was the most frequent arrhythmia found in both groups (13.57% TAVI and 41.11% SAVR). Conclusions: The present study highlights the place of TAVI in current treatment of high surgically risk patients with SA.

Author Biographies

Andra OANCEA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
“Sf. Spiridon” County Clinical Emergency Hospital, Iasi, Romania
Internal Medicine Clinic

Maria-Luiza COBZEANU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
“Sf. Spiridon” County Clinical Emergency Hospital, Iasi, Romania
Departament of Radiology

Cristina FURNICA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Institute of Forensic Medicine, Iasi, Romania

Raluca Ozana CHISTOL, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Cardiovascular Disease Institute, Iasi, Romania

M. ENACHE, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Cardiovascular Disease Institute, Iasi, Romania

A. TARUS, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Cardiovascular Disease Institute, Iasi, Romania

Flavia CORCIOVA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Cardiovascular Disease Institute, Iasi, Romania

Gr. TINICA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Cardiovascular Disease Institute, Iasi, Romania

References

1. Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: Morbidity, mortality, and costs. Clin Geriatr Med 2009; 25: 563-577.
2. Fried LP, Tangen CM, Walston J, et al. Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56(3): M146-156.
3. Anand A, Harley C, Visvanathan A, et al. The relationship between preoperative frailty and outcomes following transcatheter aortic valve implantation: a systematic review and meta-analysis. Eur Heart J 2017; 3(2):123-132.
4. Eveborn GW, Schirmer H, Heggelund G, et al. The evolving epidemiology of valvular aortic stenosis the Tromso study. Heart 2013; 99(6): 396-400.
5. Parolari A, Pesce LL, Trezzi M, et al. EuroSCORE performance in valve surgery. Ann Thorac Surg 2010; 89: 787-793.
6. Kappetein AP, Head SJ, Genereux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document. Eur Heart J 2012; 33: 2403-2418.
7. Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol 2014; 63: 747-762.
8. Chikwe J, Adams DH. Frailty: the missing element in predicting operative mortality. Semin Thorac Cardiovasc Surg 2010; 22: 109-110.
9. Vlastra W, Chandrasekhar J, Munoz-Garcia AJ, et al. Comparison of balloon-expandable vs. self-expandable valves in patients undergoing transfemoral transcatheter aortic valve implantation: from the CENTER-Collaboration. Eur Heart J 2018; 40: 456-465.
10. Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012; 366(18): 1686-1695.
11. Tzamalis P, Alataki S, BramLage P, Schmitt P, Schymik G. Comparison of valve durability and outcomes of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe symptomatic aortic stenosis and less-than-high-risk for surgery. Am J Cardiol 2020; 125(8): 1202-1208.
12. Indja B, Woldendorp K, Vallely MP, Grieve SM. New Onset Atrial Fibrillation Following Transcath-eter and Surgical Aortic Valve Replacement: A Systematic Review and Meta-Analysis. Heart Lung Circ 2020; 29(10): 1542-1553.
13. Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 2006; 1(1): 19-32.
14. Kumar N, Khera R, Garg N, et al. Comparison of outcomes of transcatheter versus surgical aortic valve replacement in patients with chronic kidney disease. Am J Cardiol 2018; 121: 343-348.
15. Kapadia S, Agarwal S, Miller DC, et al. Insights into timing, risk factors, and outcomes of stroke and transient ischemic attack after transcatheter aortic valve replacement in the PARTNER trial (Placement of Aortic Transcatheter Valves). Circ Cardiovasc Interv 2016; 9(9): e002981.
16. Wagner G, Steiner S, Gartlehner G, et al. Comparison of transcatheter aortic valve implantation with other approaches to treat aortic valve stenosis: a systematic review and meta-analysis. Syst Rev 2019; 8(1): 44 / doi: 10.1186/s13643-019-0954-3.
17. Ando T, Onishi T, Kuno T, Briasoulis A, Takagi H, Grines CL, Hatori K, Tobaru T, Malik AH, Ah-mad H. Transcatheter Versus Surgical Aortic Valve Replacement in the United States (From the Na-tionwide Readmission Database). Am J Cardiol 2021; 1(148): 110-111.
Published
2021-09-30